Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EO-3021 + dostarlimab
- Development stage
- Unknown
- Lead developer
- Elevation Oncology
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**EO-3021 + dostarlimab** is an investigational combination therapy being evaluated for advanced solid tumors, specifically in cancers expressing Claudin 18.2 such as gastric and gastroesophageal junction (GEJ) cancer. EO-3021 is an antibody-drug conjugate (ADC) that targets Claudin 18.2, delivering the cytotoxic payload monomethyl auristatin E (MMAE) via a cleavable linker. It retains antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to direct tumor cell killing as well as a bystander effect in the tumor microenvironment. Dostarlimab (brand name Jemperli) is a monoclonal antibody targeting the programmed death-1 (PD-1) receptor; it blocks the PD-1 pathway, thereby enhancing T cell-mediated anti-tumor immunity. The combination is designed to target cancer cells with EO-3021, while also releasing immune inhibition with dostarlimab, synergistically promoting anti-tumor activity. The combination is currently in early-phase clinical development.
- Brand names
- Jemperli
- Other names
- EO-3021 plus dostarlimab-gxlyEO3021 plus dostarlimab-gxlyEO 3021 plus dostarlimab-gxly
02
Targets
Claudin 18.2PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on EO-3021 + dostarlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EO-3021 + dostarlimab.